MwanzoMLLCF • OTCMKTS
add
Molecular Partners AG
Bei iliyotangulia
$ 5.89
Bei za mwaka
$ 3.40 - $ 10.14
Thamani ya kampuni katika soko
211.71M USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
SWX
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.55M | 273.73% |
Matumizi ya uendeshaji wa biashara | 4.44M | -4.84% |
Mapato halisi | -15.08M | 5.66% |
Kiwango cha faida halisi | -972.40 | 74.76% |
Mapato kwa kila hisa | — | — |
EBITDA | -15.37M | -0.62% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 159.13M | -27.07% |
Jumla ya mali | 170.62M | -25.98% |
Jumla ya dhima | 15.05M | -38.62% |
Jumla ya hisa | 155.57M | — |
hisa zilizosalia | 33.18M | — |
Uwiano wa bei na thamani | 1.26 | — |
Faida inayotokana na mali | -22.42% | — |
Faida inayotokana mtaji | -24.17% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -15.08M | 5.66% |
Pesa kutokana na shughuli | -15.72M | -18.38% |
Pesa kutokana na uwekezaji | 13.15M | 225.87% |
Pesa kutokana na ufadhili | elfu -267.00 | 2.55% |
Mabadiliko halisi ya pesa taslimu | -2.66M | 75.12% |
Mtiririko huru wa pesa | -9.80M | -15.75% |
Kuhusu
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
162
